As the cold season approaches and the spread of influenza increases, “FluGuard,” the quadrivalent recombinant flu vaccine produced by AryoGen Pharmed, is now available in pharmacies across the country.

FluGuard is a quadrivalent recombinant vaccine that provides active immunization against influenza illnesses caused by subtypes A (H1N1 and H3N2) and B (Yamagata and Victoria lineages) of the influenza virus.

 Vaccine Composition: FluGuard contains purified recombinant hemagglutinin (HA) proteins from four influenza virus strains. Because circulating influenza strains may change each season — as determined annually by the World Health Organization (WHO) — the WHO recommends annual influenza vaccination.

 Each 0.5 mL dose of FluGuard contains 180 µg of hemagglutinin protein, including 45 µg from each of the following four influenza virus strains:

A/Wisconsin/67/2022 (H1N1)pdm09-like virus

A/District of Columbia/27/2023 (H3N2)-like virus

B/Austria/1359417/2021 (B/Victoria lineage)-like virus

B/Phuket/3073/2013 (B/Yamagata lineage)-like virus

 FluGuard is a recombinant vaccine that contains no egg-derived proteins or preservatives. None of the vaccine components cause cold or flu illness.

Mechanism of Action: The recombinant hemagglutinin proteins in FluGuard act as antigens that stimulate a humoral immune response through the production of hemagglutination-inhibiting antibodies. In other words, after receiving the FluGuard vaccine, the body’s immune system produces antibodies that protect against influenza virus infection.